Base-modified factor VIII mRNA delivery with galactosylated lipid nanoparticles as a protein replacement therapy for haemophilia A

Development of a novel therapeutic strategy to treat Haemophilia A, encompassing liver-specific Gal-LNPs mediated delivery and enhanced mRNA translation for effective production of functional Factor VIII with a therapeutically relevant precision.